People · Operator
Named in public records as an officer, director or promoter · active 2014–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Icagen, Inc. | — | Pharmaceuticals | Series A | $27.5M | $224.5M | 2014 |
| Icagen-T, Inc. | — | Pharmaceuticals | Series A | $16.0M | $247.8M | 2017 |
Mark Korb at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Korb on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Cunningham | 2 | 3 |
| Timothy Tyson | 2 | 2 |
| Douglas Krafte | 2 | 2 |
| Michael Taglich | 1 | 7 |
| Vincent Palmieri | 1 | 3 |
| Edward Roffman | 1 | 3 |
| Clive Kabatznik | 1 | 3 |
| Benjamin Warner | 1 | 1 |
| Jeremiel Zimmerman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.